Ipigrix

Ipidacrine Hydrochloride, the active ingredient in Ipigrix, is a cholinesterase inhibitor presented as an oral tablet for oral administration. It works by reversibly inhibiting acetylcholinesterase, thereby increasing acetylcholine levels at neuromuscular junctions and in the central nervous system. Clinically, it is used to improve muscle strength in myasthenia gravis and to support cognitive function in patients with dementia.

GNH USA supplies Ipigrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets.

Ipigrix is a cholinesterase inhibitor used in disorders where enhanced cholinergic transmission is beneficial.

- Myasthenia gravis: improves neuromuscular transmission and reduces muscle fatigue. - Dementia (cognitive impairment): may enhance central cholinergic activity to support memory and attention.

Adverse reactions may occur with Ipigrix therapy.

Common Side Effects: - Nausea. - Vomiting. - Diarrhea. - Abdominal pain. - Dizziness. - Headache.

Serious or Rare Side Effects: - Cholinergic crisis with severe muscle weakness. - Marked bradycardia or heart block. - Respiratory depression. - Hepatic dysfunction. - Severe allergic reactions such as anaphylaxis.

Before initiating therapy, consider the following precautions. - Monitor muscle strength regularly: assess for signs of over‑stimulation. - Evaluate cognitive status periodically: document any changes. - Avoid use in patients with known hypersensitivity to Ipidacrine or related compounds. - Use caution in hepatic impairment: dose adjustment may be required. - Do not combine with other cholinesterase inhibitors without specialist advice. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipigrix may interact with several drug classes.

Major Interactions (Avoid): - Other cholinesterase inhibitors: additive cholinergic effects. - Anticholinergic agents: may diminish therapeutic benefit. - Beta‑blockers: increased risk of bradycardia.

Moderate Interactions (Monitor Closely): - SSRIs and other antidepressants: potential for serotonin syndrome. - Anesthetic agents: heightened cholinergic response. - Diuretics: possible electrolyte disturbances.